Articles related to CLINICAL TRIALS

In a phase 3 trial comparing belzutifan to everolimus for advanced renal-cell carcinoma, belzutifan demonstrated a significant improvement in progression-free survival at 18 months (24.0% vs. 8.3%, P=0.002) and objective response rate (21.9% vs. 3.5%, P<0.001).

In a phase 3 trial involving 103 pediatric patients with congenital adrenal hyperplasia, crinecerfont treatment resulted in a mean reduction of androstenedione levels by 197 ng/dL after 4 weeks, compared to an increase of 71 ng/dL in the placebo group.

In a phase 3 trial, oral sebetralstat demonstrated a median time to beginning of symptom relief of 1.61 hours for the 300 mg dose and 1.79 hours for the 600 mg dose, compared to 6.72 hours for placebo in hereditary angioedema attacks.

Apple oral immunotherapy allowed patients to tolerate an entire apple after just 39 days on average, with potential cross-tolerance to other Rosaceae fruits.

New data suggests that the Galleri blood test’s sensitivity for early-stage cancers may be lower than initially reported, potentially limiting its utility as a screening tool.

The FDA advisory committee’s decision highlights the complexities of perioperative treatment in NSCLC and the need for more precise efficacy data to guide clinical decision-making.